🇺🇸 FDA
Patent

US 12036243

BCMA CAR-T cells with enhanced activities

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 12036243 (BCMA CAR-T cells with enhanced activities) held by Allogene Therapeutics, Inc. expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Allogene Therapeutics, Inc.
Grant date
Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K38/00